Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Fatty Liver | Research

The burden of nonalcoholic steatohepatitis (NASH) in the United States

Authors: Elliot B. Tapper, Nancy Krieger, Raymond Przybysz, Nate Way, Jennifer Cai, Dion Zappe, Sarah Jane McKenna, Garth Wall, Nico Janssens, Maria-Magdalena Balp

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

There is limited data on the comparative economic and humanistic burden of non-alcoholic steatohepatitis (NASH) in the United States. The objective was to examine the burden of disease comparing NASH to a representative sample of the general population and separately to a type 2 diabetes mellitus (T2DM) cohort by assessing health-related quality of life (HRQoL) measures, healthcare resource use (HRU) and work productivity and activity impairment (WPAI).

Methods

Data came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey conducted in the United States. Respondents with physician-diagnosed NASH, physician-diagnosed T2DM, and respondents from the general population were compared. Humanistic burden was examined with mental (MCS) and physical (PCS) component summary scores from the Short-Form (SF)-36v2, concomitant diagnosis of anxiety, depression, and sleep difficulties. Economic burden was analysed based on healthcare professional (HCP) and emergency room (ER) visits, hospitalizations in the past six months; absenteeism, presenteeism, overall work impairment, and activity impairment scores on WPAI questionnaire. Bivariate and multivariable analysis were conducted for each outcome and matched comparative group.

Results

After adjusting for baseline demographics and characteristics, NASH (N = 136) compared to the matched general population cohort (N = 544), reported significantly lower (worse) mental (MCS 43.19 vs. 46.22, p = 0.010) and physical (PCS 42.04 vs. 47.10, p < 0.001) status, higher % with anxiety (37.5% vs 25.5%, p = 0.006) and depression (43.4% vs 30.1%, p = 0.004), more HCP visits (8.43 vs. 5.17), ER visits (0.73 vs. 0.38), and hospitalizations (0.43 vs. 0.2) all p’s < 0.05, and higher WPAI scores (e.g. overall work impairment 39.64% vs. 26.19%, p = 0.011). NASH cohort did not differ from matched T2DM cohort (N = 272) on mental or work-related WPAI scores, but had significantly worse physical status (PCS 40.52 vs. 44.58, p = 0.001), higher % with anxiety (39.9% vs 27.8%, p = 0.043), more HCP visits (8.63 vs. 5.68, p = 0.003) and greater activity impairment (47.14% vs. 36.07%, p = 0.010).

Conclusion

This real-world study suggests that burden of disease is higher for all outcomes assessed among NASH compared to matched general controls. When comparing to T2DM, NASH cohort has comparable mental and work-related impairment but worse physical status, daily activities impairment and more HRU.
Appendix
Available only for authorised users
Literature
5.
go back to reference Radu C, Grigorescu M, Crisan D, Lupsor M, Constantin D, Dina L. Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. J Gastrointestin Liver Dis. 2008;17(3):255–60.PubMed Radu C, Grigorescu M, Crisan D, Lupsor M, Constantin D, Dina L. Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. J Gastrointestin Liver Dis. 2008;17(3):255–60.PubMed
11.
go back to reference Health K. The global health and wellness report findings from the National Health and Wellness Survey (NHWS). 2017. Health K. The global health and wellness report findings from the National Health and Wellness Survey (NHWS). 2017.
12.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed
14.
go back to reference Maruish M, editor. User’s Manual for the SF-36v2 Health Survey. 3rd ed. Quality Metric Incorporated; Lincoln: 2011. [Google Scholar] Ware: User’s manual for the SF-12v2 Health Survey. Maruish M, editor. User’s Manual for the SF-36v2 Health Survey. 3rd ed. Quality Metric Incorporated; Lincoln: 2011. [Google Scholar] Ware: User’s manual for the SF-12v2 Health Survey.
15.
go back to reference Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14(6):1523–32.CrossRefPubMed Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14(6):1523–32.CrossRefPubMed
17.
go back to reference Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.CrossRefPubMed Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.CrossRefPubMed
19.
go back to reference Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–65.CrossRefPubMed Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–65.CrossRefPubMed
25.
go back to reference Patton HM, Nyberg AH, Caparosa S, et al. Healthcare Resource Utilization, Demographics, and Comorbidities in Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) and Progressive Stages in a Large, Integrated Healthcare Delivery System. Gastroenterology. 2018;154(6):S1223–4. https://doi.org/10.1016/S0016-5085(18)34037-X.CrossRef Patton HM, Nyberg AH, Caparosa S, et al. Healthcare Resource Utilization, Demographics, and Comorbidities in Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) and Progressive Stages in a Large, Integrated Healthcare Delivery System. Gastroenterology. 2018;154(6):S1223–4. https://​doi.​org/​10.​1016/​S0016-5085(18)34037-X.CrossRef
31.
go back to reference Martin LM, Leff M, Calonge N, Garrett C, Nelson DE. Validation of self-reported chronic conditions and health services in a managed care population11The full text of this article is available at http://www.elsevier.com/locate/ajpmonline. Am J Prevent Med. 2000;18(3):215–8. https://doi.org/10.1016/S0749-3797(99)00158-0.CrossRef Martin LM, Leff M, Calonge N, Garrett C, Nelson DE. Validation of self-reported chronic conditions and health services in a managed care population11The full text of this article is available at http://​www.​elsevier.​com/​locate/​ajpmonline.​ Am J Prevent Med. 2000;18(3):215–8. https://​doi.​org/​10.​1016/​S0749-3797(99)00158-0.CrossRef
33.
go back to reference Rinella ME, Loomba R, Caldwell SH, et al. Controversies in the Diagnosis and Management of NAFLD and NASH. Gastroenterol Hepatol (N Y). 2014;10(4):219–27.PubMed Rinella ME, Loomba R, Caldwell SH, et al. Controversies in the Diagnosis and Management of NAFLD and NASH. Gastroenterol Hepatol (N Y). 2014;10(4):219–27.PubMed
Metadata
Title
The burden of nonalcoholic steatohepatitis (NASH) in the United States
Authors
Elliot B. Tapper
Nancy Krieger
Raymond Przybysz
Nate Way
Jennifer Cai
Dion Zappe
Sarah Jane McKenna
Garth Wall
Nico Janssens
Maria-Magdalena Balp
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02726-2

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.